SecBot SecBot
Biotech Drug Report Generated Aug 28, 2026

CTX310

CRSP·CRISPR Therapeutics AG
NEUTRAL
Drug Impact Rating1/10
Trial phase
Unknown, no clinical trials or regulatory filings found for CTX310.
Time to market
Unknown, no clinical data or development timeline has been publicly disclosed for CTX310.
Why 1/10
No scheduled catalyst or clinical data exists for CTX310 in any public database, the drug is either preclinical, undisclosed, or non-existent, so there is no dated binary event to assess.
Actionable Insight NEUTRAL

CTX310 does not appear in any public database, clinical trial registry, SEC filing, or press release as of this report. Investors should verify the drug name and check CRISPR Therapeutics' official pipeline page or recent corporate presentations for any mention before taking a position. The company's key approved product is CASGEVY (CTX001), and its most advanced clinical-stage asset is CTX131.

Price Chart

Loading chart...

Executive Summary

CTX310 is not found in any public database, clinical trial registry, SEC filing, or press release. Extensive searches across SecBot's internal databases (trials, FDA catalysts, press releases, SEC filings, events) and external web searches returned zero results for this drug name. CRISPR Therapeutics AG (Nasdaq: CRSP) is confirmed as the developer, but its publicly disclosed pipeline includes CTX001 (approved CASGEVY), CTX110, CTX120, CTX130, and CTX131, not CTX310. The drug may be a very early preclinical program, an internal code name not yet disclosed, or a non-existent/incorrectly referenced name. Without any verifiable data, no informed investment thesis can be built around this specific asset.

How It Works

Unknown. Based on CRISPR Therapeutics' naming convention, CTX310 would likely be a gene-edited cell therapy or in vivo gene-editing candidate using CRISPR/Cas9 technology, but no mechanism has been publicly disclosed.

Trial Status

No clinical trial records, FDA filings, or press releases referencing CTX310 were found in any public or SecBot database.

The Two-Sided Case

▲ Bull Case3
CRISPR Therapeutics (CRSP) is a well-funded, Nasdaq-listed gene-editing pioneer with one approved product (CASGEVY/CTX001) and a deep pipeline.
The company has a strong analyst consensus with 17 Buy/Strong Buy ratings vs 0 Sell, and a mean price target of $87.56 (34.7% upside from ~$60.90).
If CTX310 is a real preclinical program, it would benefit from CRISPR Therapeutics' established gene-editing platform and manufacturing expertise.
▼ Bear Case3
No evidence of CTX310 exists in any public database, clinical trial registry, or SEC filing, the drug may not be a real or active program.
CRISPR Therapeutics has a broad pipeline but no CTX310 program has been disclosed; if it exists it is likely preclinical with no near-term catalyst.
CRSP stock has a high short-volume ratio (60-73% in late July 2026), indicating significant bearish positioning.

Upcoming Catalysts

  • No catalysts identified for CTX310 specifically. For CRISPR Therapeutics broadly: CTX131 clinical data updates and CASGEVY commercial rollout are the key near-term value drivers.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 globenewswire.com